van der Leest RJT - Search Results

1

Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands.

van den Reek JMPA, van der Leest RJT, Thomas SE, Prevoo R, Plantenga ME, de Jong EMGJ. van den Reek JMPA, et al. Among authors: van der leest rjt. Adv Ther. 2024 Apr;41(4):1594-1605. doi: 10.1007/s12325-023-02759-9. Epub 2024 Feb 24. Adv Ther. 2024. PMID: 38402373

2

[A man with a rare disfiguring cutaneous manifestation of sarcoidosis].

Mo C, van der Kraaij GE, van der Leest RJT. Mo C, et al. Among authors: van der leest rjt. Ned Tijdschr Geneeskd. 2022 Jul 27;166:D6573. Ned Tijdschr Geneeskd. 2022. PMID: 35899722 Dutch.

3

Risks of different skin tumour combinations after a first melanoma, squamous cell carcinoma and basal cell carcinoma in Dutch population-based cohorts: 1989-2009.

van der Leest RJT, Hollestein LM, Liu L, Nijsten T, de Vries E. van der Leest RJT, et al. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):382-389. doi: 10.1111/jdv.14587. Epub 2017 Oct 17. J Eur Acad Dermatol Venereol. 2018. PMID: 28898461

4

[Increasing incidence of thin melanomas in the Netherlands].

Zoutendijk J, van der Leest RJT, Nijsten T, Mooi WJ, van der Rhee JI, de Vries E, Hollestein LM. Zoutendijk J, et al. Among authors: van der leest rjt. Ned Tijdschr Geneeskd. 2017;161:D1030. Ned Tijdschr Geneeskd. 2017. PMID: 28537538 Dutch.

5

Comparing survival of patients with single or multiple primary melanoma in the Netherlands: 1994-2009.

Pardo LM, van der Leest RJ, de Vries E, Soerjomataram I, Nijsten T, Hollestein LM. Pardo LM, et al. Br J Dermatol. 2017 Feb;176(2):531-533. doi: 10.1111/bjd.14846. Epub 2016 Dec 22. Br J Dermatol. 2017. PMID: 27377396 No abstract available.

6

Increasing time trends of thin melanomas in The Netherlands: What are the explanations of recent accelerations?

van der Leest RJ, Zoutendijk J, Nijsten T, Mooi WJ, van der Rhee JI, de Vries E, Hollestein LM. van der Leest RJ, et al. Eur J Cancer. 2015 Dec;51(18):2833-41. doi: 10.1016/j.ejca.2015.09.008. Epub 2015 Nov 14. Eur J Cancer. 2015. PMID: 26589973

7

Cohort studies (and skin cancer) never come alone.

Verkouteren JAC, van der Leest RJT, Nijsten T. Verkouteren JAC, et al. Among authors: van der leest rjt. J Invest Dermatol. 2015 Mar;135(3):649-651. doi: 10.1038/jid.2014.482. J Invest Dermatol. 2015. PMID: 25666670 Free article.

8

Risk of subsequent cutaneous malignancy in patients with prior melanoma: a systematic review and meta-analysis.

van der Leest RJ, Flohil SC, Arends LR, de Vries E, Nijsten T. van der Leest RJ, et al. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1053-62. doi: 10.1111/jdv.12887. Epub 2014 Dec 10. J Eur Acad Dermatol Venereol. 2015. PMID: 25491923 Review.

9

Conditional survival of malignant melanoma in The Netherlands: 1994-2008.

van der Leest RJ, van Steenbergen LN, Hollestein LM, de Vries E, Nijsten T, van Akkooi AC, Janssen-Heijnen ML, Coebergh JW. van der Leest RJ, et al. Eur J Cancer. 2014 Feb;50(3):602-10. doi: 10.1016/j.ejca.2013.10.019. Epub 2013 Nov 18. Eur J Cancer. 2014. PMID: 24262585

10

Screening for second primary melanomas: is it efficient? Reply from authors.

van der Leest RJ, Nijsten T, de Vries E. van der Leest RJ, et al. Br J Dermatol. 2013 May;168(5):1135. doi: 10.1111/bjd.12139. Br J Dermatol. 2013. PMID: 23614564 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page